Quantcast
Last updated on April 17, 2014 at 12:58 EDT

Latest Cordis Stories

2012-09-12 23:03:39

Research reveals an aging population and increasing obesity rates fuel the 1.1 Billion dollar Endovascular devices market in Europe. (PRWEB) September 11, 2012 Most peripheral vascular devices in Europe are used for the treatment of peripheral arterial disease (PAD). PAD is characterized by the hardening and thickening of arteries resulting from the accumulation of fatty tissue and cholesterol. The prevalence of PAD increases with age and the existence of predisposing conditions such as...

2012-08-20 02:30:21

TEL AVIV, Israel, August 20, 2012 /PRNewswire/ -- InspireMD, Inc. (OTCBB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary MGuard(TM) embolic protection stent platform technology for use in patients with Acute Myocardial Infarctions, announced today that a multi-center randomized trial of its MGuard(TM) embolic protection stent demonstrated a positive outcome in treating patients suffering heart...

2012-02-15 12:45:00

Survey Reveals Most Cardiologists Would Use a Bioabsorbable Stent for Coronary Angioplasty According to iData Research Vancouver, BC (PRWEB) February 15, 2012 According to a new market monitoring service from iData Research (http://www.idataresearch.net), the leading global authority in medical device market research, Cordis, Boston Scientific and Abbott Vascular were the preferred stent brands in the U.S., Europe, Middle East and Africa, while Medtronic had a strong market presence in...

2011-06-15 08:01:00

NEW BRUNSWICK, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that it expects to record an after-tax restructuring charge in the range of $500-$600 million in the second quarter of 2011 as a result of restructuring plans announced by its subsidiary, Cordis Corporation. The restructuring charge will be treated as a special item. In its separate news release today, Cordis announced the discontinuation of its clinical development program for...

2011-06-15 08:00:00

BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO(TM) Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. The company will also stop the manufacture of CYPHER® and CYPHER SELECT® Plus...

2011-05-16 08:00:00

PARIS, May 16, 2011 /PRNewswire/ -- Cordis announces the launch in Europe of Radial Solutions, a complete portfolio for transradial interventions. New to the portfolio is the Cordis RADIALSOURCE(TM) Transradial Access Kit. RADIALSOURCE(TM) Transradial Sheaths are designed to provide physicians with atraumatic and smooth access to the radial artery during diagnostic and interventional procedures and is a result of Cordis' long standing commitment to driving innovation. The rate of...

2011-05-16 08:00:00

PARIS, May 16, 2011 /PRNewswire/ -- - Cordis Continues its History of Innovation With Two New Products: EMPIRA(TM) and RADIALSOURCE(TM) Cordis announced it has obtained CE mark for its EMPIRA(TM) and EMPIRA(TM) NC RX PTCA* Dilatation Catheters for the treatment of coronary artery disease. The EMPIRA(TM) systems are designed to enable interventional cardiologists to open patients' narrowed coronary arteries during angioplasty and stenting procedures. The EMPIRA(TM) family of...

2011-01-28 14:59:00

MARSHALL, Texas, Jan. 28, 2011 /PRNewswire/ -- A federal jury in Marshall, Texas has returned a $482 million verdict for Dickstein Shapiro LLP client Dr. Bruce N. Saffran against defendants Johnson & Johnson and its subsidiary, Cordis Corporation, in Saffran v. Johnson & Johnson and Cordis Corp., No. 2:07-CV-451 (TJW) (E.D. Texas), before Judge T. John Ward. Significantly, the jury found that the Cypher(TM) drug-eluting cardiac stent, manufactured and distributed by Cordis Corp.,...

2010-09-30 02:58:00

WATERLOO, Belgium, September 30, 2010 /PRNewswire/ -- - SORT OUT IV Data Presented at TCT in Washington DC Shows Remarkable Clinical Safety and Efficacy Measures With Both CYPHER(R) Stent and XIENCE V(R) Stent - Only CYPHER Stent has More Than 10 years of Clinical Safety Data in 70 Studies Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE V (R) Everolimus-eluting Stent in the primary...

2010-09-02 06:59:00

STOCKHOLM, September 2, 2010 /PRNewswire/ -- - Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the...